ABSTRACT

Objective: Traditional systems of medicine all over the world even traditional medicine and cancer have been using plants and plants products for therapeutic intention. The purpose of these retrospective trials is to assess the clinical efficacy of chemotherapy in conjunction with TCM for a broad variety of cancers.

Methods: 75 patients with available cancers were concluded in the study during September 1993 – May 2018. The sex ratio of male: female was 50:25 respectively. The mean age at onset was 46.9 years (range 10-79 years. All patients were treated with different dosage of various chemotherapy in combination with TCM or traditional medicine alone. The basic chemotherapeutic regimen consisted of vincristine (VCR, 1-2 mg/week), cyclophosphamide (CTX, 200-1, 000mg/week), mitomycin C(MMC, 2-4mg/week) and 5-fluorouracil(5-FU,250-500mg/ day). The detail prescription of TCM varied among a broad variety of carcinomas. The criteria of complete remission (CR) and/or partial remission (PR) is according to the rules where physicians have in common with in clinics. In 75 cases, the CR was obtained in 33(44%) advanced cancers, a short CR in 11(14.7%) cases, PR in 25 (33.3%) cancers, stable disease in 6 cases. The crude herbs consisted of sargassum, tangle, Oyster (mussels), Poria cocos, Ophiopogon japonicus, Prunella vulgaris, Taraxacum, Scrophularia ningpoensis, Cremastrea appendiculata, Trichosanthes Kirilowii, Sophora subprostrata, Houttuynia cordata, Scutellaria barbata d. don and Oldenlandia diffusa roxb.

Results: Among those long-term survivors, 31 carcinomas obtained in disease-free survival over 5 years, 20 cancers were survival over 10 years, the longest four patients over 25 years.

Conclusion: In this study, it was experienced that a CR was a pivotal influencing factor in those longest survival patients, and traditional medicine was also recommended. Down regulating oncogenic receptors may be useful paradigm and perspective in currently the third line setting of clinical target therapy and in rendering our better understanding of cancer biology.

Keywords: Cancer chemotherapy, target therapy, traditional medicine.

INTRODUCTION

Chemotherapy is a major skillful of cancer therapy. One of the most important advances in oncology has been increased acceptance of evidence that most patients with disseminated tumors were setted to the protocol of chemotherapy in conjunction with recent targeting oncogenic receptor, traditional medicine(‘TCM’) and/or adoptive immunotherapy (LAK cells, TIL therapy). The experience in Ugandan children with Hodgkin's disease has been excellent and in a study of 14 adults with stage I and II Hodgkin's disease, mostly clinically staged, 13 patients (93%) achieved CR with combination chemotherapy and all were in CR 11 to 94 months after the completion of treatment. Another, a disease-free survivors of 5 years (56.5-59.3% versus 22-24.3%) and 10 years (48.9%) was remarkably higher rate in those breast cancers with stage III following surgery plus chemotherapy than only surgery. More promising, in large trials of 48 HER2-positive early breast cancer patients, targeting the adjuvant trastuzumab treatment demonstrated highly favorable outcome. Five year overall survival rates and disease-free survival rates were 95.8% and 93.8% respectively. Recently, neratinib was recently approved by FDA for extended adjuvant treatment of ER+/HER2+ breast cancer. Others advanced or metastatic gastric cancer constitutes the majority of patients in clinical practice. Systemic chemotherapies and combined regimens are currently available, provide palliation and prolong survival. In particular, high-quality clinical trials on TCM in cancer are generally lacking, except for
Kampo medication for Japanese cancer patients, arsenic trioxide (As2O3) in the role of acute promyelocytic leukemia and cantharidin in treatment of liver cancer. This paper will attempt to place in proper interpretative review from those patients with cancers under remission in this group.

MATERIALS AND METHODS
Total 75 patients with available cancers were concluded in the study during September 1993- May 2018. The sex ratio of male: female was 50:25 respectively. The mean age at onset was 46.9 years ranging from 10 to 79 yrs. Among age distribution, although there is some uncertain about the type distribution of cancers, it was found 38.1 years as the mean age at onset for lymphoma, 44.0 years for liver cancer, while higher mean age at 60.1 years has been shown in lung cancer in this group. The clinical diagnoses in a broad variety of carcinomas consisted of metastatic nasopharyngeal cancer 5 cases, metastatic breast cancer 4, lung tumors 12, hematopoietic malignancies 25 cases (acute leukemias FAB M1 type 2, M2 type 1, acute promyelocytic leukemia 1, chronic myeloid leukemia CML 2, chronic lymphocytic leukemia CLL 1, multiple myeloma 2, lymphoma 16), thyroid cancer 2, maxillary sinus carcinoma 1, carcinoma of mandibular sinus 2, laryngeal carcinoma 1, gallbladder cancer 1, cholangiocarcinoma 1, metastatic oral cancer 1, cholangiocarcinoma of mandibular sinus 1, metastatic hepatic cancer 5 cases, among age distribution, the rate of complete regression was in 25(33.3%) patients with a broad variety of carcinoma, while three patients (1 malignant lymphoma, 1 carcinoma of mandibular sinus, 1 metastatic tumor of bone) had survival time 12, 18+ and 11+ years respectively, implicating a longer survivor in patients the survival with tumours. Otherwise, stable disease was 6 cases. Basic characteristics of studied population were summarized in Table 1. During the schedule of drug administration, all patients were treated with the different dosage of 1 to 4 courses of various combination chemotherapy in conjunction with traditional medicine. In statistically analysis, one patient with nasopharyngeal cancer, the diplopia and unable version in his eye were recovered to "normal" visual acuity following the combination chemotherapy of VCMF (VCR, CTX, MMC and 5-Fu) plus traditional medicine. A patient with rodent ulcer once obtained complete response as to an approach of 5% Fu of retinoic acid ointment. A short CR was achieved by the protocol of MFC (MMC; 5-Fu; Ara C/homoharringtonine, CTX) plus cantharidin or cinobufacini drug in 5 advanced gastric cancers. One of them was a long-term survivor for 6 yrs via mass incision and the combination of MFC with herbs Scutellaria barbata d. don. In view of cancer types, 10 lymphoma was setted to the major protocol of the combination conventional chemotherapy (COMA, VCR, CTX, MMC or ADM) in conjunction with traditional medicine which to relieve the chemotherapeutic toxicity, and reinforced the efficacy of chemotherapy. One lymphoma was regressed only by prednisone (200#). Another 4 patients with thumb lymphadopathy was treated by the use of antibiotics regimen in full dose with anti-inflammatory herbal tablets or immunotherapy lymphocyte transfer factor. In 12 HCC, 6 HCC were treated mainly by 5-Fu (500-1,000mg/day) and TCM. 2 patients obtained CR through cantharidin and traditional medicine. The main protocol of TCM with adjuvant antibiotics regimen and low dose of dexamethasone was given in a primary liver cancer (AFP+, ascites ++++, jaundice ++, liver tumor 3.2x3.0cm). One acute promyelocytic leukemia complicated with metastatic liver cancer (7x4.5cm) was in CR with all-trans retinoic acid (ATRA) and TCM. The detail prescription of TCM was mentioned before. In the follow up, one HCC accompanied with colon polyps obtained complete remission via hapatectomy and targeting oncogenic receptor tyrosine kinase inhibitor sorafenib. Dose intensity has proven to be critical in maximizing chemotherapeutic efficacy for numerous human cancers. Eight other patients with cancers were in remission through small dosage of chemotherapy and TCM or traditional medicine (TCM) alone. There were 4 lung cancers, 1 gallbladder cancer, 1 cholangiocarcinoma and 2 thyroid cancers. Among targeting two metastatic lung cancer, one female with lung cancer was given the combination chemotherapy plus targeting oncogenic receptor EGFRv III gefitinib, which was stable disease for 8+ years.

RESULTS
In 75 cancers, the rate of complete remission (CR) was achieved in 33(44%) advanced cancers. All CR patients with advanced cancers was survival over 5 years, 18 cancers was survival 10 years. Another, a short CR was obtained in 11 (14.7%) advanced cancers, the survival time varied from 20 months to 4 yrs. PR was obtained in 25(33.3%) patients with a broad variety of carcinoma, while three patients (1 benign lymphoma, 1 carcinoma of mandibular sinus, 1 metastatic tumor of bone) had survival time 12, 18+ and 11+ years respectively, implicating a longer survivor in patients the survival with tumours. Otherwise, stable disease was 6 cases. Basic characteristics of studied population were summarized in Table 1. During the schedule of drug administration, all patients were treated with the different dosage of 1 to 4 courses of various combination chemotherapy in conjunction with traditional medicine. In statistically analysis, one patient with nasopharyngeal cancer, the diplopia and unable version in his eye were recovered to "normal" visual acuity following the combination chemotherapy of VCMF (VCR, CTX, MMC and 5-Fu) plus traditional medicine. A patient with rodent ulcer once obtained complete response as to an approach of 5% Fu of retinoic acid ointment. A short CR was achieved by the protocol of MFC (MMC; 5-Fu; Ara C/homoharringtonine, CTX) plus cantharidin or cinobufacini drug in 5 advanced gastric cancers. One of them was a long-term survivor for 6 yrs via mass incision and the combination of MFC with herbs Scutellaria barbata d. don. In view of cancer types, 10 lymphoma was setted to the major protocol of the combination conventional chemotherapy (COMA, VCR, CTX, MMC or ADM) in conjunction with traditional medicine which to relieve the chemotherapeutic toxicity, and reinforced the efficacy of chemotherapy. One lymphoma was regressed only by prednisone (200#). Another 4 patients with thumb lymphadopathy was treated by the use of antibiotics regimen in full dose with anti-inflammatory herbal tablets or immunotherapy lymphocyte transfer factor. In 12 HCC, 6 HCC were treated mainly by 5-Fu (500-1,000mg/day) and TCM. 2 patients obtained CR through cantharidin and traditional medicine. The main protocol of TCM with adjuvant antibiotics regimen and low dose of dexamethasone was given in a primary liver cancer (AFP+, ascites ++++, jaundice ++, liver tumor 3.2x3.0cm). One acute promyelocytic leukemia complicated with metastatic liver cancer (7x4.5cm) was in CR with all-trans retinoic acid (ATRA) and TCM. The detail prescription of TCM was mentioned before. In the follow up, one HCC accompanied with colon polyps obtained complete remission via hapatectomy and targeting oncogenic receptor tyrosine kinase inhibitor sorafenib. Dose intensity has proven to be critical in maximizing chemotherapeutic efficacy for numerous human cancers. Eight other patients with cancers were in remission through small dosage of chemotherapy and TCM or traditional medicine (TCM) alone. There were 4 lung cancers, 1 gallbladder cancer, 1 cholangiocarcinoma and 2 thyroid cancers. Among targeting two metastatic lung cancer, one female with lung cancer was given the combination chemotherapy plus targeting oncogenic receptor EGFRv III gefitinib, which was stable disease for 8+ years.
months. Thyroid cancer was placed on the primary use of traditional medicine. The crude herbs consisted of sargassum, tangle, Oyster (mussels), Poria cocos, Ophiopogon japonicus, Prunella vulgaris, Taraxacum, Scrophularia ningpoensis, Cremastrea appendiculata, Trichosanthes kirilowii, Sophora subprostrata, Houttuynia cordata, Scutellaria barbata d. don and Oldenlandia diffusa roxb.

The survival times in those patients with remission were less than 1 years 10 cases, 1 to 3 years 20 cases, over 3 to 5 years 12 cases, over 5 to 10 years 11 cases, over 10 to 20 years 13 cases, and over 20 years 7 cases. In differential types of 20 patients with over 10 years survivors, lymphoma occupied 8 cases (40%). Among 7 patients with over 20 years, lymphoma occupied 3 cases, metastatic breast cancer 2 cases and hepatocellular carcinoma 2 cases.

CASE REPORTS

A 55 years old woman was diagnosed as having metastatic palatum cancer on November 6, 1993 when she presented with tumors both in her cavity of the mouth and neck lymphadenopathy. On examination revealed 2 lymph nodes (4x3 cm) enlargement in her left neck. A 3x5cm mass was found in her palate malle which was covered over uvula palatina. Moreover, the left side of her face also had a thumb lymph nodes palpable. Cures can be achieved by use of combination chemotherapy (VCR, CTX, 5-Fu, phytohemagglutinin, PHA) and in 18 years later she died of recurrent episodes of oral cancer.

A 43-year-old man entered the hospital due to his metastatic nasopharynx cancer on July 4, 1995. At first onset he developed symptoms of marked headache; right neck lymphadenopathy (thumb size). The patient received no radiotherapy. With the relief symptoms of headache and regression of his lymphadenopathy, the diplopia and unable version in his eye were recovered to "normal" visual acuity under the combination chemotherapy of VCMP (VCR, CTX, MMC, 5-Fu) with the addition of TCM. He obtained a 3years survivor. A 35-year-old woman was admitted to the hospital because of her relapsed gastric cancer, with recurrent fever for one month duration. In March, 1996 she was undergoing surgery in a local hospital due to her tarry stools. At post-operatively, a rodent ulcer (5x4x2.8cm) with harden border was detected in lesser curvature of the stomach, accompanied with adjacent metastatic lymph nodes. NHL was diagnosed according to her stomach tissue specimens. The definitive diagnosis of her malignant tumor was based on a provincial tumor hospital. She had a past history of tuberculosis. CR was obtained after small dosage of MFC (5-Fu, MMC, CTX) in combination with cinobufacini intravenously, oral daily demethylcantharidin and traditional herbs. As an outpatient, she had continued to traditional herbs Scutellaria barbata d. don. She was a long-term survivor for 6 years and died of tuberculosis (type IV). A 58-year-old man was diagnosed as having malignant lymphoma on April 29, 1997. He presented his past history of lymph node palpable (a pea size) in right neck region 8 years ago. Later in 1995, a gradually increased thumb lymph node was palpable, accompanied by his left neck metastasis. At physical examination, on admission, showed 4,5x3cm, 2x3cm, 2x3cm palpable lymph node in right neck and a 2x3cm lymph node in left neck region. Lymphoma was diagnosed according to his lymph node aspirates. He obtained remission following combination chemotherapy (CTX and 5-Fu) in conjunction with traditional medicine. He was stable disease with tumors for 12 years survivor. A 75-year-old woman entered the hospital due to her metastatic nasopharynx cancer in June, 1997. On admission she presented with anemia following melena, fatigue and weakness. A thumb lymph node behind her right ear was palpable. CR was obtained through TCM and small dosage of chemotherapy CTX and 5-Fu, and enlarged lymph node was disappeared. She was a 4 years survivor. Traditional medicine consisted of Prunella vulgaris, Asparagus mannanusceus, Rehmannia glutinosa, Ophiopogon japonicus, Lycium chinenses, Centipede, cantharides, Scutellaria barbata d. don, Oldenlandia diffusa roxb. A 71-year-old man was admitted to the hospital on December 29, 1997 because of the relapse of his lymphoma for 2 months duration. He once obtained partial remission (PR) using chemotherapy in another tumor hospital. CR was obtained by the main protocol of TCM with small dosage of chemotherapy (CTX, 5-Fu). TCM consisted of Asparagus mannanusceus, Ophiopogon japonicus, Asparagus, Coix lachryma, Paris polyphylla, pseudobulb of Appendiculate crenastra, Trichosanthes kirilowii, Indigowood leaf, Scutellaria barbata d. don, Oldenlandia diffusa roxb. He was a survivor of 7 yrs.

A 62-year-old woman entered the hospital because of her chronic myelocytic leukemia (CML) on October 21, 2000. She developed her distended abdomen and splenomegaly 6 months duration. On B ultrasound examination showed that spleen reached to umbilicus, with irregular liver scan. Hemoglobin concentration was 70g/l. Leukocyte count 160,000 (160x109/l) with 19% blasts and promyelocytes, 28.5% myelocytes and metamyelocytes. Platelet count was 375x109/l. Bone marrow aspirations revealed marked hypercellularity with myeloid hyperplasia. Blast forms (blast and promyelocytes) constituted approximately 19.6% of all cells, and immature myelocyte and metamyelocytes occupied 28.5% of all cells. Megakaryocytes was hyperplasia. The diagnosis of CML with accelerate stage was made. CR was obtained after busulfan in conjunction with TCM. She was in satisfactory health until 4 years before admission. When she was found to be splenomegaly. At that time, WBC 120x109/l. The high percentage of blast cells corresponded to the beginning of her relapse. Oral busulfan was administered in the following a total dose of 120mg, with CR again. She was survivor for near 8 years. A 65-year-old woman was diagnosed as having gallbladder cancer in July 20, 2002. She developed symptoms of lancinating abdominal pain and intensive distended abdomen and tender with muscle defense in upper quadrants.
| Cancer types  | Cases No | Sex  | Mean ages (years) | Treatment Protocol | Response following therapy | Duration of remission(years) |
|--------------|----------|------|------------------|--------------------|--------------------------|-----------------------------|
| Lymphoma     | 16       | M14, F2 | 38.1(13-66)      | COMA(10)*, Radiotherapy**(1), prednisone(1), Immunotherapy(4) | CR(10)*, short CR(2), PR(4) | 1 3 2 1 9 |
| HCC          | 12       | M10, F2 | 44.0(26-63)      | a.5-Fu(250-1000mg/ day), VCR,CTX,MMC,TCM b. Cantharidin, TCM c. hepectomcy, sorafenib | CR(8), Short CR(2), PR(1), stable disease(1) | 1 4 1 3 3 |
| Lung tumors  | 12       | M8,F4  | 60.1(40-79)      | a. COMF, TCM b.DDP, etoposide, IL-2/gefitinib; c.CTX,5-FU, antitumor capsule; d.TCM alone | CR(2), short CR(2), PR(3), stable disease (5) | 4 3 3 1 |
| NPC          | 5        | M3, F2 | 51.4(38-75)      | a. VCMF, TCM b.CTX,5-FU,TCM | CR(1), short CR(1), PR(3) | 1 3 1 |
| MBC          | 4        | F4     | 31.3(25-41)      | a. COMF, TCM b.COP, TCM | CR(3),PR(1) | 1 2 |
| Stomach cancer | 5       | M2, F3 | 42.3(35-500)     | a.MFC, TCM b.CTX, 5-FU, antitumor capsule | CR(1),short CR(2),PR(2) | 1 3 1 |
| AML          | 3        | M2, F1 | 4, 18, 20        | DA**, HA, TCM | PR(3) | 3 |
| APL          | 1        | M      | 31               | ATRA 80mg/day; H 1mgx5days; TCM | CR | 1 died of relapsed APL |
| CML          | 2        | M1, F1 | 33, 62           | Busulfan, TCM | CR (1), short CR(1) | 1 1 |
| CLL          | 1        | M      | 58               | Chlorambucil, TCM | CR | 1 died of stomach cancer |
| MM           | 2        | M1, F1 | 60, 63           | Thalidomide, pred, TCM | Short CR(1), PR(1) | 1 1 |
| Epidermoid cancer | 1 | F     | 72               | 5% FU of retinoic acid ointment | PR | 1 |
| Thyroid cancer | 2      | F2    | 54, 60           | TCM alone | CR(2) | 1 1 |
| Bile cancer  | 1        | F      | 65               | CTX,5-FU,TCM | CR | 1 |
| Cholangio-carcinoma | 1 | M     | 72               | MFC (MMC, 5-FU, CTX) | CR | 1 died of intestinal cancer |
| Others***    | 7        | M5,F2  | 57.5(44-69)      | COFP,COMMB,TCM | CR(1), PR(6) | 1 2 1 3 |

Note: HCC: hepatocellular carcinoma; NPC: metastatic nasopharyngeal cancer; MBC: metastatic breast cancer; AML: acute myeloid leukemia; APL: acute promyelocytic leukemia; CML: chronic myeloid leukemia; CLL: chronic lymphocytic leukemia; MM: multiple myeloma; COMA:CTX, VCR, MMC, ADM; COMF:CTX, VCR, MMC/ADM, 5-FU; VCMF:VCR,CTX,MMC/DDP; 5-FU; COP: CTX, VCR, pred; COFP:CTX, VCR, 5-FU, PHA, Pred: DA:DNR, 45mg/m², Ara-c 100mg/m²; HA: homoharringtonone 1mg x 5days,Ara-c 50mg, intramuscle, twice a day; MFC:MMC,5-FU,Ara-c/CTX; COMBB:CTX, VCR, MMC, MTX, Bleomycin; ATRA: all-trans retinoic acid; Pred: prednisone; TCM: traditional medicine; M: male; F: female; *: cases number; **: treatment in another hospital; ***include oral cancer 1, relapsed vulva cancer 1, laryngeal cancer 1, maxillary sinus carcinoma 1, carcinoma of mandibular sinus 2, and metastatic bone tumor 1.
On CT scan demonstrated that her ascites=++, gallbladder was dilation, with irregular thick choleystic inner wall, and many nodules were found in the cavity of bile. She was given the combination of TCM with small dosage of 5-Fu and CTX drugs. Three months later, in view of improvement of her general symptoms, she obtained CR. She is in health during follow up of 15years.

A 25-year-old man was admitted to the hospital on October 4, 2003 because of his relapsed malignant lymphoma. He complained of his enlarged lymph nodes once regression using herbs in 1997. He had a past experience of combination chemotherapy due to lymph node enlargement in bilateral neck, which was diagnosed as having malignant lymphoma (B cell type. In September, 2003, he developed his nasopharynx the markedly inflamed redness, swelling, and with obstruction. At physical examination revealed 5 firm lymph nodes to varying degree in size of a pea to a walnut in his left neck, and 2 palpable lymph nodes (1.5x2cm) in his right neck. A 3x4.5cm mass was found in his soft palate molle which was flecked with small red ulcer patches. CR can be achieved by use of antibiotics regimen in full dose and combination chemotherapy (VCR, CTX, 5-Fu, MMC), the tumors was disappeared as like the mouth of health individuals. He was a 3 years of survivors.

A 72-year-old man was admitted to the hospital due to his jaundice cholangio carcinoma on September 2, 2004. He had a history of bad cough two months ago, followed by a progressive general jaundice, conspicuous weight loss, and no appetite and urine icterus. On CT examination showed his complete obstructive choledodus and his cholangiectasis due to the cause of obstructive tumor (1.5x2cm). He was given the treatment of antibiotics in full dose, combination chemotherapy (5-Fu, CTX, MMC) with TCM. CR was achieved two months later, and as an outpatient, he was to be continued the traditional herbs. Traditional medicine consisted of Astragalus membranaceus, Ophiopogon japonicus, Asparagus, poria cocos, Lyceum chinenses, Wheat sprout, Salvia bowleyana, Scutellaria baicalensis, Artemisia capitllaries, Gardenia jasminoides, Hypericum japonicum, Houttuynia cordata, Scutellaria barbata d. don, Oldenlandia diffusa roxb. In the follow up, she was a 15 years survivor.

A 58-year-old man was diagnosed as having chronic lymphocytic leukemia (CLL) on January 16, 2011 because of recent leukocyte counts elevated to 118x10^9/l. The patient complained of his leukocytosis (67-97x10^9/l) for more than one month duration. He was treated with hydroxyccarbamide in another hospital and leukocytosis declined to 27x10^9/l. The most common physical signs revealed two thumb lymph nodes palpable in his left neck. Hemogram: Hemoglobin concentration (Hb) was 87g/l. Leukocyte count (WBC) 123.88x10^9/l. The leukocyte differential count: 9% segmented neutrophils, 90% small lymphocytes. The platelet count 131x10^9/l. Bone marrow aspiration revealed hypercellularity. Bone marrow differential count: 14% myeloid, 7.2% erythroid, approximately 76.8% of predominant cell was small lymphocytes. The diagnosis of CLL was made. CR was obtained by the use of chlorambucil tablets and traditional medicine. On April 9, 2011, repeat hemogram: Hb 112g/l; WBC 13.6x10^9/l, plt 128x10^9/l. On May 5 and July 28, 2011, Hb 104-112g/l; WBC 9.54-10.1x10^9/l, with a leukocyte differential count of 26.2% mature neutrophils and 63.8% lymphocytes; plt 101-112x10^9/l respectively. Bone marrow aspirates on May 14, 2011 revealed normal cellularity. Bone marrow differential count: 34% myeloid, 31.2% erythroid, 33.6% lymphocytes. As an outpatient, he continued traditional herbs. He was well until on October 15, 2011 while an attack of stomach pain and tarry stools was admitted to another hospital. Routine hematologic studies at that time, Hb 69g/l; WBC 7.3x10^9/l with 70% mature neutrophils and 28% lymphocytes; plt 188x10^9/l. Repeat bone marrow aspirates on October 15, 2011 revealed normal cellularity. Bone marrow differential counts: 50% myeloid, 21% erythroid, 27.5% lymphocytes. He died of another stomach cancer.

**DISCUSSION**

In this study, a series of the long follow up of patients with cancers were reported. I experienced that a CR was a pivotal influencing factor in those longest survival patients, and traditional medicine was also recommended. The traditional combination chemotherapy program for lymphomas of favorable histologic type has been CVP (CTX, VCR, Pred) given at 21-days intervals. Cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) were used in the NCI study for patients with nodular mixed and nodular histocytic lymphomas. More intensive CVP programs with the addition of Adriamycin or bleomycin, or both, known as BACOP or CHOP-bleo, resulted in overall complete remission rates for patients with diffuse lymphomas ranging from 48% to 89%. The NCI program of this 5-drug program, complete remission rates with these approaches has ranged from 48% to 94%. In this study, the CR rates was 63% in 16 lymphomas, 6 CR were used by CVP or COMA regimens. The use of chemotherapy to treat stomach cancer has no firmly established standard of care. Some drugs used in stomach cancer treatment have
included: 5-Fu (fluouracil), doxorubicin (Adriamycin), mitomycin C and most recently oxaliplatin, irinotecan in various combination. The relative benefits of these different drugs, alone or in combination, are unclear. There are evidences supporting that clinical researches are exploring the benefits of giving chemotherapy as adjuvant therapy for surgery to destroy remaining cancer cells. In recent analyses of definitive surgery followed by adjuvant radio chemotherapy (5-Fu/leucovorin LV regimens) for patients with gastric cancer, Liu and Ahmed reported that 59.3% (48/81) patients survived >3 years, 18.5% (15/81) patients survived 5 or more years. Eighteen out of 81 (22.2%) patients are still alive with a medium survival of 142 months (57-196 months). In this study, 5 patients with gastric cancer obtained a short CR through MFC regimen plus cinobufacini and cantharidin drugs. One relapsed gastric cancer survived over 6 years after surgery and adjuvant chemotherapy. More recent, treatment with HER2 inhibitor, trastuzumab, has been demonstrated to improve overall survival in inoperable locally advanced or metastatic gastric carcinoma overexpressing the HER2. Oncogenic receptor HER2 is over expressed in 13-22% of patients with gastric cancer. Taranz and colleagues reported two HER2-positive metastatic gastric adenocarcinoma who favorably responded to second line chemotherapy (FOLFIRI, irinotecan plus 5-Fu) with trastuzumab continuation following progressive disease to first line treatment containing trastuzumab, implicating trastuzumab continuation in metastatic HER positive gastric cancer is safe, practical and improve survival.

Oncogenic EGFR mutations are found in 10% to 35% of lung adenocarcinomas, with predominants in a subset of patients with non-small cell lung cancer (NSCLC). These mutations, which commonly occur as either small in-frame deletions in exon 19 or point mutations T790M or L858R in exon 21 within the EGFR tyrosine kinase domain, confer constitutive activity and sensitivity to EGFR tyrosine kinase inhibitor(s) (TKI). Konduri and colleagues reported five patients with metastatic lung cancer whose tumors harbored EGFR fusion, most commonly RAD5, are recurrent in lung cancer. Four of whom were treated with EGFR TKI erlotinib with documented antitumor response for 5, 6, 8, and 20 months respectively. An early EGFR TKI trial randomized patients with EGFR mutation positive stage IIIb or IV adenocarcinoma to treatment with afatinib or gemcitabine and cisplatin, treatment with afatinib prolonged progression free survival to 11.0 months as opposed to 5.6 months with gemcitabine and cisplatin. In the phase III trial of 419 patients with advanced T790M positive NSCLC with osimertinib vs platinum based therapy, progression free survival in the osimertinib group was 8.5 months, compared to the platinum-based therapy group at 4.2 months. Serra reported the clinical response of a lapatinib-based therapy in lung metastatic lesions of a Li-Fraumeni syndrome patient with oncogenic HER2V659E mutation and an EGFR-exon 20 insertion. A symptomatic and radiologic clinical response was achieved using oral daily lapatinib at a dose of 1,000mg in combination with intravenous weekly paclitaxel 80mg/m², lately, trastuzumab initial dose of 8mg/Kg intravenously, and then followed by 6mg/kg every three weeks. In total, the clinical benifits lasted over 9 months. In Cuba, CimaVax-EGF, promising, an active vaccine targeting EGF as the major ligand of oncogenic EGFR, it is in use as a cancer therapy against non-small cell lung cancer (NSCLC). In this study, we use gefitinib in keeping stable disease for 8+ months in a woman with lung adenocarcinoma, and using gefitinib in more patients are under investigation. Interesting, in an APL complicated with secondary HCC, it has been demonstrated previously that nuclear RARB has been shown to be rearranged as a result of insertion of HBV sequences. Recent promising, these oncogenic receptor derivatives in addition to pml/RARA, oncogenic TBL1XR1-RARB, and NUP98/RARG, and PML-RARG were also detected in APL rare cases. The involvement of RARB may explain why the disappearance of malignant hepatic tumour cells via the use of ATRA agent. In this case, ATRA (80-100mg/ day) was resistance to the relapse episode. In the presence of genetic mutation in RARA LBD and the PML-B2 domain of PML-RARA, one explanation for ATRA resistance is that the N-CoR/SMAT-corepressor complex tightly interact with pml/ RARA or PLZF, even under pharmacological concentration of ATRA, so that transcriptional repression cannot occur at RARA target gene promoter. ATRA binding LBD impaired, degradation of pml/ RARA by proteasome pathway are inhibited. Previous studies uncovered that the ATRA and 13-cis forms of retinoic acid, two isomers of RA, are equally effective inhibiting proliferation.

In addition, new emerging aberrant pml/ RARA in relapsed APL returned to act as a constitutive transcriptional repressor by pertubing normal retinoid signaling and RAR function, suppressing (the blockade of) differentiation, possessing an altered specificity for DNA response element, these DNA recognition changes target a distinct set of “neoplastic” genes that differ from the genes normally targeted by normal RARA. In literature alternative strategy, an APL obtained CR after treatment with 13-cis retinoic acid first and repeated CR with ATRA in relapse. And more, 80% (4/5) CR in newly APL and 33% (4/12) CR in relapsed APL were achieved after treatment with 9-cis retinoic acid (LGD1057) alone. Nowadays, a lot of cohort trials, 61.5% (24/39) achieved CR using tamibarotene including 5 newly APL and 13 relapse APL twice or more. Among 269 APL with CR underwent maintenance random, four year relapse-free survival rate was 84% (ATRA) and 91% (Tamibarotene). In 52 high risk patients, this became significant (50% for ATRA, 87% for tamibarotene). In comparative analysis among those relapsed APL, 80% (28/35) achieved CR and 22.86% CRm in tamibarotene-ATO versus 54.2% (19/35)CR with only 2.86-3.7% CRm in ATRA and ATO regimen. In particular, an appreciable benefits of tamibarotene-ATO regimen might occur at significantly lower frequency of
leukocytosis with development of retinoid acid syndrome, an important adverse reaction during treatment of APL. Thus, Tamibarotene demonstrated more efficacy in both untreated APL patients and relapsed who have been treated ATRA and chemotherapy, especially as novel strategy in relapsed APL in Japan and others. This is encouraging perspective.

CONFLICTS OF INTEREST
The author declares that there is no conflict of interest regarding the publication of this paper.

REFERENCES
1. Zhu G, Saboor-Yaraghi AA, Yarden Y, Santos J, Neil JC. Downregulating oncogenic receptor: From bench to clinic. Hematol Med Oncol 2016; 1(1): 30-40.
2. Zhu G, Saboor-Yaraghi AA, Yarden Y. Targeting oncogenic receptor from molecular physiology to currently the standard of target therapy. Adv Pharm J 2017; 2(1):10-28.
3. Van den Heuvel CNAM, Das AI, de Bitter T, Simmer F, Wurdinger T, et al. Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes. Sci Rep 2018; 8(1):7072.
4. Toledo RA, Garralda E, Mitsu M, Pons T, Monsech J, et al. Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of anti-angiogenic therapies. Clin Cancer Res 2018; 24(15):3550-9.
5. Cross DA, Ashton SE, Ghiorgihi S, Eherlein C, Nebhan C, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046-1061.
6. Conterato AJ, Belanger AR, Yarmus LB, Akulian JA. Update on NSCLC tissue acquisition, processing, and profiling in the molecular age. Hematol Med Oncol 2016; 1(2):1-8.
7. Pat SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI. Efficacy of BGI398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial cancer with FGFR3 alteration. Cancer Discov, May 30 2018.
8. Liu J, Sareddy GR, Zhou M, Viswanadhapalli S, Li X, et al. Differential effects of estrogen receptor beta isoforms on glioblastoma progression. Cancer Res 2018; 78(12): 3176-89. https://doi.org/10.1158/0008-5472.CAN-17-3470
9. Weir HM, Bradbury RH, Lawson M, Rabow AA, Butter D, et al. AZD9496. An oral estrogen receptor inhibitor that block the growth of ER-positive and ESR1-mutant breast tumors in preclinical models. Cancer Res 2016; 76:3307-3318. https://doi.org/10.1158/0008-5472.CAN-15-2357
10. Went DC, Kocherginsky M, Tonsing-Carter EY, Dolcen N, Hosfield DJ. Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonist in ER-negative breast cancer. Clin Cancer Res 2018; 24(14): 3433-3446. https://doi.org/10.1158/1078-0432.CCR-17-2793
11. Reddy JA, Allagadda VM, Leamon CP. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr Pharm Biotechnol 2005;6:131-150
12. Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, et al. Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients. Clin Cancer Res 2018; 24(13): 3014-25. https://doi.org/10.1158/0008-5472.CAN-17-2499
13. Zhu G, Saboor-Yaraghi A, Dharmadhikari D, Baer J. A pilot study of chemotherapy and traditional plant medicine in hematologic malignancy: report of thirty-four cases. Hematol Med Oncol 2017; 2:2. https://doi.org/10.15761/HMO.1000102
14. Zhu G. EpCAM-an old cancer antigen, turned oncogenic receptor and its targeting immunotherapy. Univ J Pharm Res 2018; 3(2):43-48. https://doi.org/10.15711/ajph.2018.052
15. Rosenberg SA. Observation on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with metastatic cancer. N Engl J Med 1985; 313:1485.
16. Forget MA, Haymacke C, Hess YK, Meng YJ, Creasy C, et al. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clin Cancer Res 2018; 24(18): 4416-28.
17. Olweny CLM, Katongole-Mbidde E, Mirre C. Childhood Hodgkin's disease in Uganda: a ten-year experience. Cancer 1978; 4:787-792. https://doi.org/10.1002/1097-0424(197808421-2 <787::aid-cncr282042051.2.0.CO;2-m>
18. Laura F, Baccarani M, Fiacchini M. Combination chemotherapy in stage I or II Hodgkin's disease. Lancet 1979; 2:1072-1073. https://doi.org/10.1016/S0140-6736(79)92466-8
19. Kato M, Sakuyama A, Matsutani T, Minato H. Efficacy of Trastuzumab therapy in HER2-positive early breast cancer patients in our clinic. Proceedings of BIT's 8th Annual World Cancer Congress 2013; 301.
20. Singh H, Walker AJ, Amri-Kordestani L, Cheng J, Tang S, et al. US Food and Drug Administration Approval: Neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer. Clin Cancer Res 2018; 24(15):3486-91. https://doi.org/10.1158/1078-0432.CCR-17-3628
21. Takeda T, Yamaguchi T, Yagasaki N. Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines. Int J Clin Oncol 2012; 17:143-49. https://doi.org/10.1007/s10147-011-0271-x
22. Ito A, Munakata K, Imazu Y, Watanabe K. First nationwide attitude survey of Japanese physicians on the use of traditional Japanese medicine (Kampo) in cancer treatment. Evidence-based complementary and alternative medicine. Hindawi, 2012. https://doi.org/10.1155/2012/2957082
23. Zhu G, Mische SE, Hindwai, Ito A, Yaraghi AA, Yarden Y, et al. Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients. Lungs and Breathing 2017; 76:199. https://doi.org/10.15761/LBJ.1000115
24. Zhang Q, Zhu G. The pathological pattern of seven malignant cancers following Demethylcantharidin. Adv Pharm J 2017; 2:6(243-247. https://doi.org/10.16000/pq.02025.0102604.1
25. Zhu G, Musumeci F, Byrne P, Gupta D, Gupta E. Treatment of advanced hepatocellular carcinoma (HCC) with the combined protocol of chemotherapy 5-fluorouracil and traditional medicine: report of ten cases. Clin Trials Pathol Case Stud 2017; 2(2):61-65. https://doi.org/10.3904/jkpm.2014.29.2.149
26. Zhu G, Musumeci F, Byrne P, Gupta D, Gupta E. Role of traditional herbal medicine in the treatment of advanced hepatocellular carcinoma (HCC): past and future ongoing. Advance Pharmaceutical J 2017; 2(3):115-120. https://doi.org/10.1002/cam4.2108
27. Zhu G, Musumeci F, Byrne P, Gupta D, Gupta E, Baer J. A pilot study of lung cancer following chemotherapy and traditional medicine: report of 12 cases. Lungs and Breathing 2017; 1(3):1-4. https://doi.org/10.15761/LBJ.1000115
28. Zhu G, Musumeci F, Byrne P, Gupta D, Gupta E, Baer J. A pilot study of lung cancer following chemotherapy and traditional medicine: report of 12 cases. Adv Pharm J 2017; 2(5):199-203. https://doi.org/10.15761/LBJ.1000115
29. Bonadonna G, Lattuada A, Monfardini S, et al. Combined radiotherapy-chemotherapy in localized non-Hodgkin’s lymphomas: five-year results of a randomized study. In: Adjuvant Therapy of Cancer II. Edited by Jones SE, Salmon SE. Gower and MacMillan, New York; 1979:145-153.

30. Anderson T, Bender RA, Fisher RI, et al. Combination chemotherapy in non-Hodgkin’s lymphoma: results of long-term follow up. Cancer Treat Rep 1977; 61:1057-1066. PMID: 71205.

31. Skarin AT, Rosenthal DS, Moloney WC, et al. Combination chemotherapy of advanced non-Hodgkin’s lymphoma with bleomycin, Adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP), Blood 1977; 49:759-69. PMID: 66957.

32. Rodriguez V, Cabanillas F, Burgess MA, et al. Combination chemotherapy (CHOP-bleo) in advanced (non-Hodgkin’s) malignant lymphoma. Blood 1979; 49:325-33. PMID: 65189.

33. Schein PS, De Vita VT Jr, Hubbard S, et al. Bleomycin, Adriamycin, Cyclophosphamide, Vincristine, and Prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histocytic lymphoma. Ann Intern Med 1976; 85:417-22. https://doi.org/10.7326/0003-4819-85-4-417.

34. Case DC Jr. Combination chemotherapy of advanced diffuse non-Hodgkin’s lymphoma: results of cyclophosphamide, Adriamycin, vincristine, prednisone, and bleomycin (CHOP-bleo). J Clin Oncol 1979; 7:49-52. PMID: 92513.

35. Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017; 8:CD004064. https://doi.org/10.1002/14651858.CD004064.pub3.

36. Scarotti M, Galizia E, Verdeccia L, Berardi R, Antognoli S, et al. Chemotherapy for advanced gastric cancer: across the years, a standard of care? Expert Opin Pharm 2007; 8(6):797-808. https://doi.org/10.1517/14656566.8.6.797.

37. Oridtura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, et al. Treatment of gastric cancer. World J Gastroenterol 2014; 20(7):1635-49. https://doi.org/10.3748/wjg.v20.i17.1635.

38. Liu JL, Ahme S. Long term survival of patients with gastric cancer treated with adjuvant radio-chemotherapy: proposal of a prognostic index with implication for treatment modification Oncology Res Rev (ORR) 2018; 1(2):1-5. https://doi.org/10.15761/1400100109.

39. Skreynek N. The oncogenic receptor ErbB2 modulates gemicitabine and irinotecan/ SN-38 chemo resistance of human pancreatic cancer cells via NCNT1 transporter and multidrug resistance associated protein MRP-2. Onco Target 2015; 6(21):21519-21531. https://doi.org/10.18632/oncotarget.3414.

40. Meza-Junco J, Au HJ, Sawyer MB. Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Manag Res 2011; 3:57-64. https://doi.org/10.2147/CMR.S12698.

41. Fusco N, Rocco EG, Del Conte C, Pellegrini C, Bulfamante G, et al. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mol Pathol 2013; 26(6):816-24. https://doi.org/10.1038/modpathol.2012.228.

42. Tanz R, Mahfoud T, Alami EL, Bazine A, Errihani H, et al. Is there any advantage from continuation of trastuzumab beyond progression in metastatic her positive gastric cancer? Hematol Med Oncol 2018; 3, 2. https://doi.org/10.15761/HMO.1000159.

43. Gabinova I, Gorin A, Astsaturov I. Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res 2014; 20:28-34. https://doi.org/10.1158/1078-0432.CCR-13-0122.

44. Shimizu N, Kondo I. Hyperproduction of EGFR receptor in human gastric cell is regulated by a translocation chromosome, t (7; 11) (p 22; q32). Cytojen Cell Genetics 1982; 32:316-317. https://doi.org/10.1007/801534472.

45. Merlino GT, Xu YH, Ishii S, Clark AJ, Sembra K, et al. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 1984; 224:417-419. https://doi.org/10.1126/science.6200934.

46. Ulrich A, Coussens J, Hayflick JS, Dull TJ, Gray A, et al. Human epidermal growth factor receptor 1 (HER1) DNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984; 309:418-425. https://doi.org/10.1038/309418a0.

47. Miltra S, Han S, Soderstram K, Wong A. Preferential expression of an oncogenic receptor in brain tumor stem cells: identification and targeting using an engineered antibody. In: Proc Am Assoc Cancer Res. Cancer Res 2011; 72. https://doi.org/10.1111/j.1755-5949.2011.00955.x.

48. Hembrough T, Thyparambil S, Liao WL, Darfler M, et al. Quantitative multiplexed SRM analysis of oncogenic receptors in FFPE colorectal carcinoma tissue. AACR 103rd Annual Meeting Chicago, IL. Cancer Res 2012; 72:5537. https://doi.org/10.1158/1538-7445.AM2012-5537.

49. Lee JC, Vivanco I, Beroukhim R, Huang JH, Fenn WL, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in extracellular domain. PLoS Medicine 2006; 3:e485. https://doi.org/10.1371/journal.pmed.0030045.

50. Godin-Heymann N, Bryant I, Rivero MN, Ulkus L, Bell DW, et al. Oncogenic activity of epidermal growth factor receptor kinase inhibitor deletions and mutations in lung cancer. J Exp Med 2014; 207:1427-1437. https://doi.org/10.1084/jem.20140097.

51. Godin-Heymann N, Bryant I, Rivero MN, Ulkus L, Bell DW, et al. Oncogenic activity of epidermal growth factor receptor kinase inhibitor deletions and mutations in lung cancer. J Exp Med 2014; 207:1427-1437. https://doi.org/10.1084/jem.20140097.

52. Serra V, Vivancos A, Puembla X, Felip E, Silberschmidt D, et al. Clinical response to a lapatinib-based therapy in a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov 2013; 3:1238-1244. https://doi.org/10.1158/2159-2890.CD-13-0132.

53. Rodriguez PC, Rodriguez C, Gonzalez G, Laze A. Clinical development and perspective of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 2010; 12:17-23. PMID: 20387330.

54. Gonzalez G, Crobket T, Laze A. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving last long lasting treatment. Cur Cancer Drug Targ 2011; 11:103-110. https://doi.org/10.2174/156800911793743583.

55. De H, Marchio A, Tiollais P, Dejean A. A novel steroid hormone receptor: related by the 770QM drug resistance mutation, Cancer Res 2007; 67:7319-7326. https://doi.org/10.1158/0008-5472.CAN-06-4625.

56. Such E, Cervova T, Sotlar K. Anticancer immunity in human acute promyelocytic leukemia lacking RAR alpha resistance mutation. Cancer Res. 2010; 70:10122-10132. https://doi.org/10.1158/0008-5472.CAN-10-1558.

57. Samuels PJ, Samuels SK. PPAR gamma ligands in cancer treatment: clinical trials and mechanisms. Front Pharmacol 2016; 7:181. https://doi.org/10.3389/fphar.2016.00181.

58. Samuels PJ, Samuels SK. PPAR gamma ligands in cancer treatment: clinical trials and mechanisms. Front Pharmacol 2016; 7:181. https://doi.org/10.3389/fphar.2016.00181.

59. Samuels PJ, Samuels SK. PPAR gamma ligands in cancer treatment: clinical trials and mechanisms. Front Pharmacol 2016; 7:181. https://doi.org/10.3389/fphar.2016.00181.
leukemia blasts with NUP98/RARG fusion gene Ann Hematol 2014; 93:1931-33. https://doi.org/10.1007/s00277-014-2073-5

62. Ha JS, Do YR, Ki CS, Lee C, Kim DH, et al. Identification of a new type of RARG fusion in acute promyelocytic leukemia. Leukemia 2017; 31(9):1992-95. https://doi.org/10.1038/leu.2017.167

63. Tomita A, Kiyoi H, Nao T. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. Int J Hematol 2013; 97(6):717-25. https://doi.org/10.1007/s10547-012-1354-4

64. Chomienne C, Balleiri P, Balltrand N, Daniel MT, Fenaux P, et al. All-trans retinoic acid in acute promyelocytic leukemia II. In vitro studies, structure-function relationship. Blood 1990; 76:1710. https://doi.org/10.1182/blood.V76.9.1710.bloodjournal7691710

65. Haiahc T, Lffler H, Glass B, Gassmann W. Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse. Clin Invest 1993; 71:774-9. https://doi.org/10.1007/BF00190317

66. Soignet SL, Benedetti F, Fleischauer A, Parker BA, Truglia JA, et al. Clinical study of 9-cis retinoic acid (LGD) in acute promyelocytic leukemia. Leukemia 1998; 12:1518-21. https://doi.org/10.1038/leu.2001150

67. Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997; 90:967-73.PMID: 9242525

68. Takeuchi M, Yano T, Omo E, Takahashi K, Kibata M. Relapse of acute promyelocytic leukemia previously treated with ATRA: clinical experience with a new synthetic retinoid, Am80. Leuk Lymphoma 1998; 31:441-51. https://doi.org/10.1080/10428199809057604

69. Takeuchi M, Yoshida I, Takahashi K. Long-term follow up of re-induction with a new synthetic retinoid, Am-80 for relapse of acute promyelocytic leukemia previously treated with all-trans retinoic acid; results of 7 cases from a single institute. Rinsho Ketsueki 2003; 44(11):1069-73. https://doi.org/10.1140/inketsu.44.1069

70. Takeshita A, Shiragawa K, Adachi M, Ono T, Kiguchi T, et al. Tamibarotene for the treatment of acute promyelocytic leukemia: expert opinion on orphan drugs 2014; 2(9):961-69. https://doi.org/10.15172/16787071.2014.943733

71. Naoe T. Tamibarotene for the treatment of acute promyelocytic leukemia: maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol 2014; 32:3729-35. https://doi.org/10.1200/JCO.2013.0175-0233-7

72. Sanford D, Lo-coco F, Sanz MA, Bona ED, Coutre S, et al. Tamibarotene in patients with acute promyelocytic leukemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. Br J Hematol 2015; 171, 4. https://doi.org/10.1111/bjh.13607

73. Wang JX, Mi YC, Jiang B, Chen XC, Ji CY, et al. Tamibarotene compared to all-trans retinoic acid (ATRA) as add-on to arsenic trioxide (ATO) in subjects with relapsed acute promyelocytic leukemia(APL). Blood 2015; 126(23):220. https://doi.org/10.1182/blood.V126.23.220

74. Kojima M, Ogiya D, Ichiki A, Hara R, Amaki J. Refractory acute promyelocytic leukemia successfully treated with combination therapy of arsenic trioxide and tamibarotene. Leukemia Research Reports 2016; 5:11-13. https://doi.org/10.1016/j.lrr.2016.01.001

75. Asou N. Retinoic acid, all-trans retinoic acid (ATRA) and Tamibarotene. Chemotherapy for leukemia. Springer. Front online 2017; 183-211. https://doi.org/10.1007/978-981-10-3332-2_11

76. Grignani F, Ferrucci P, Testa U, et al. The acute promyelocytic leukemia-specific PML-RARA fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74:423-431. https://doi.org/10.1016/0092-8674(93)90104-f

77. Rousselot P, Hardas H, Patel A, et al. The PML-RARA gene product of the (15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediates transactivation in human myeloid cells. Oncogene 1994; 5:945-51. PMID: 8290265

78. He LZ, Guizè D, Tribioli C, Peruzzi D, Pandolfi PP. Distinct interactions of PML-RARA and PLZF-RALpha with co-repressors determine differential response to RA in APL. Nature Genetics 1998; 18:126-35. https://doi.org/10.1038/ng0928-126

79. Kitareewan S, Pitha-Rowe I, Sekula D, et al. UBEIL is a retinoid target that triggers PML/RALpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci USA 2002; 99:3806-3811. https://doi.org/10.1073/pnas.020512199

80. Segalla S, Rinaldi L, Kalsner N, et al. Retinoic acid receptor alpha fusion to PML affects its transcriptional and chromatin-remodeling properties. Mol Cell Biol 2003; 23: 8795-8808. https://doi.org/10.1128/MCB.23.23.8795-8808.2003

81. Jing Y. The PML-RARα fusion protein and target therapy for acute promyelocytic leukemia. Leuk Lymphoma 2004; 45: 639-48. https://doi.org/10.1080/10428190490982494

82. Carbone R, Botrugo OA, Ronzoni S, et al. Recruitment of the histone methyltransferase SUV39H1 and its the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 2006; 26:1245-1282. https://doi.org/10.1128/MCB.26.4.1245-1269.2006

83. Nasr R, Guilemin MC, Ferhi O, et al. The eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Med 2008; 14:1333-42. https://doi.org/10.1038/nm.1891

84. Marstrand TT. A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. Leukemia 2010; 24:1265. https://doi.org/10.1038/leu.2010.95

85. Lallemand-Breitenbach V, De the H. A new oncoprotein catabolism pathway. Blood 2010; 116:2200-2201. https://doi.org/10.1182/blood-2010-07-294025

86. Rosen M, Privalsky ML. Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: prospective and perspective. J Thyroid Res 2011. https://doi.org/10.4061/2011/2011309

87. Podhorecka M, Macheta A. Acute promyelocytic leukemia: modern approach to disease pathogenesis and differentiation treatment. Postepy Hig Med Dosw 2013; 67:1083-1089. https://doi.org/10.1111/j.1744-1599.2012.02244.x

88. Dos Santos GA, Kats L, Pandolfo PP. Synergy against PML-RARA targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med 2013; 210:2793-2802. https://doi.org/10.1084/jem.20131121

89. Humbert M. The tumor suppressor gene DAPK2 is induced by myeloid transcription factor Pu.1 and c. EBPs during granulocytic differentiation but repressed by PML-RARα in APL. J Leuk Biol 2014; 95:83-93. https://doi.org/10.1007/s10870-013-0190-9

90. Braekeleer E, Dou-Guilbert N, De Braekeleer M. RARA fusion genes in acute promyelocytic leukemia: A review. Expert Rev Hematol 2014; 7:347-357. https://doi.org/10.1586/17474866.2014.903794

91. Noguera NS, Piredda ML, Taulli RC, Lo-Coco F. PML/RARα inhibits PTEN expression in hematopoietic cells by competing with Pu.1 transcriptional activity. Oncotarget 2015; 7(44):63836-397. https://doi.org/10.18632/oncotarget.11964